19 citations
,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
4 citations
,
December 2021 in “Journal of Cosmetic Dermatology”
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
36 citations
,
April 2021 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
21 citations
,
February 2021 in “BMJ case reports” Anabolic steroid users may face higher risk of severe COVID-19.
49 citations
,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
29 citations
,
November 2020 in “Journal of the European Academy of Dermatology and Venereology” Women with high androgen levels may have more severe COVID-19 symptoms.
12 citations
,
November 2020 in “Annals of Oncology” Androgen deprivation therapy might be better for preventing COVID-19 than treating it.
26 citations
,
October 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
6 citations
,
October 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Early treatment improved COVID-19 outcomes, and spironolactone helped reduce risks in females with high androgen levels.
134 citations
,
July 2020 in “Journal of Cosmetic Dermatology” Male pattern hair loss could hint at androgens affecting COVID-19 severity.
254 citations
,
October 2014 in “Menopause” The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.